Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Gilead Sciences (GILD) or Vertex Pharmaceuticals (VRTX) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven stra ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value, $0.001 per share GILD The Nasdaq Global Select Market FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ ...

If you like to see more ideas, please subscribe to the premium service "Value in Corporate Events" here and try the free trial. In this service we cover major earnings events, M&A, IPOs and other significant corporate events with actionable ideas. Furthermore, we provide coverage of situations and names on request!As the leader of the investing group Value In Corporate Events they provide members with opportunities to capitalize on IPOs, mergers & acquisitions, earnings reports and changes in corporate capi ...

Gilead Sciences, Inc. (GILD) reported better-than-expected third-quarter results and raised its annual earnings guidance.Adjusted earnings per share (EPS) of $2.02 beat the Zacks Consensus Estimate of $1.58. In the year-ago quarter, the company reported adjusted earnings of $2.29 per share.The year-over-year decrease was due to higher acquired IPR&D and tax expenses.Total revenues of $7.5 billion beat the Zacks Consensus Estimate of $7 billion. Revenues also increased 7% year over year, primarily due to hig ...

Gilead Sciences Today | --- | --- | |---------------------------|-------| | | | | | | | | | | GILD Gilead Sciences | | | $97.09 +5.40 (+5.89%) | | | 52-Week Range $62.07 | | | ▼ | | | $98.31 | | | | | | Dividend Yield 3.17% | | | P/E Ratio | | | 118.40 | | | Price Target | | | $88.65 | | | | | Add to Watchlist Gilead Sciences NASDAQ: GILD recently broke its 52-week high and is up over 40% over the past six months. As a leading biopharmaceutical company dedicated to pioneering innovative therapies, Gilead bo ...

Analyst’s Disclosure: I/we have a beneficial long position in the shares of GILD either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. The contents of this article, my previous articles, and my comments are for informational purposes only and may not be considered investment a ...

Q324 Financial Results November 6, 2024 Forward-Looking Statements Statements included in this presentation that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: Gilead's ability to achieve its anticipated full ...

Financial Data and Key Metrics Changes - Gilead reported total product sales of $7.5 billion in Q3 2024, reflecting a 7% year-over-year increase, driven by growth across HIV, Oncology, and Liver Disease [16][66] - Non-GAAP diluted EPS was $2.02, down from $2.29 in the same period last year, primarily due to higher acquired IPR&D and tax expenses [73] - The company raised its full-year guidance for total product sales to a range of $27.8 billion to $28.1 billion, an increase of $650 million at the midpoint compared to the prior range [77][81] Business Line Data and Key Metrics Changes - HIV sales reached $5.1 billion, up 9% year-over-year, driven by higher average realized prices and increased demand [16][18] - Oncology sales were $860 million, up 6% year-over-year, primarily due to Trodelvy's growth [33] - Liver Disease portfolio sales were $733 million, up 4% year-over-year, with strong demand for the viral hepatitis portfolio [26] Market Data and Key Metrics Changes - The U.S. PrEP market grew 13% year-over-year, with Descovy for PrEP capturing over 40% market share [23] - Veklury sales increased 9% year-over-year to $692 million, with year-to-date sales of $1.5 billion exceeding initial full-year guidance [31][32] - The HIV treatment market is expected to grow at an annual rate of 2% to 3% [22] Company Strategy and Development Direction - Gilead aims to deliver at least 10 transformative therapies by 2030, with six innovative therapies launched since 2019 [10] - The company is focusing on expanding its HIV treatment portfolio with four new regimens by the end of 2030 [22] - Gilead is prioritizing resources for promising programs in Oncology, including Trodelvy and Anito-Cel, while discontinuing less promising developments [12][53] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong performance and operational execution, leading to increased guidance across multiple metrics [6][75] - The company is optimistic about the launch of Lenacapavir for PrEP, anticipating significant market expansion opportunities [24][92] - Management acknowledged competitive pressures in the cell therapy space but remains focused on expanding utilization and access [37][116] Other Important Information - The FDA granted breakthrough therapy designation to Lenacapavir for HIV prevention, with a regulatory submission planned before the end of the year [8][45] - Livdelzi was launched in the U.S. for primary biliary cholangitis, with initial demand exceeding internal expectations [9][28] - Gilead's operating margin for Q3 was 43%, with expectations for continued strong performance in the fourth quarter [71] Q&A Session Summary Question: CAR T space impacts on Yescarta - Management discussed in-class competition from new indications and increased manufacturing capacity, while out-of-class competition includes bi-specific therapies [85][86] Question: Launch dynamics for Lenacapavir for PrEP - Management highlighted the potential for rapid market adoption and plans for a seamless launch experience for providers and consumers [91][95] Question: Anito-cel and delayed neurotoxicity - Management believes the construct of Anito-cel contributes to the lack of observed delayed neurotoxicity, with confidence in its best-in-class profile [100][101] Question: Scaling Anito-cel manufacturing - Management confirmed that learnings from Yescarta and Tecartus have been applied to Anito-cel production, allowing for efficient scaling [104][105] Question: Payer coverage for Seladelpar - Management reported positive initial payer coverage dynamics for Livdelzi, with expectations for modest contributions in 2024 and more meaningful contributions in 2025 [111][112] Question: Regulatory filing for Anito-cel - Management indicated that the regulatory filing will be based on 12 months of data, with plans to address reimbursement access challenges [115][116] Question: Expectations for the HIV analyst event - Management plans to provide both qualitative and quantitative insights on the commercialization of Lenacapavir for PrEP at the upcoming event [120][122]

Gilead Sciences (GILD) reported $7.55 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 7%. EPS of $2.02 for the same period compares to $2.29 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $6.99 billion, representing a surprise of +7.94%. The company delivered an EPS surprise of +27.85%, with the consensus EPS estimate being $1.58. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings - ...

Gilead Sciences (GILD) came out with quarterly earnings of $2.02 per share, beating the Zacks Consensus Estimate of $1.58 per share. This compares to earnings of $2.29 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 27.85%. A quarter ago, it was expected that this HIV and hepatitis C drugmaker would post earnings of $1.61 per share when it actually produced earnings of $2.01, delivering a surprise of 24.84%. Over the last fou ...